Walker Marlan D 4

4 · TherapeuticsMD, Inc. · Filed Feb 20, 2025

Form 4

Period: 2025-02-18

Chief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2025-02-18+3,467→ 66,032 total
Exercise/Conversion
Common Stock
2025-02-18+2,311→ 68,343 total
Exercise/Conversion
Common Stock
2025-02-18+770→ 69,113 total
Exercise/Conversion
Common Stock
2025-02-18+1,733→ 70,846 total
Exercise/Conversion
Performance Stock Units
2025-02-18−3,467→ 0 total
Exercise: $0.00→ Common Stock (3,467 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-18−2,311→ 0 total
Exercise: $0.00→ Common Stock (2,311 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-18−770→ 0 total
Exercise: $0.00→ Common Stock (770 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-18−1,733→ 1,733 total
Exercise: $0.00→ Common Stock (1,733 underlying)

Footnotes (4)

[F1]Each performance stock unit ("PSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs.
[F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024.
[F3]Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024.
[F4]Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024.

Documents

1 file